In the present study, we identified the serum metabolite biomarkers predictive of response to anti-PD-1 treatment in patients with advanced NSCLC based on metabolomic profiling using UHPLC-MS. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.